Attached files
file | filename |
---|---|
EX-31.2 - EXHIBIT 31.2_SECTION 302_CFO CERTIFICATION - PLUS THERAPEUTICS, INC. | exhibit312_cfocertification.htm |
EX-31.1 - EXHIBIT 31.1_SECTION 302_CEO CERTIFICATION - PLUS THERAPEUTICS, INC. | exhibit311_ceocertification.htm |
10-Q - CYTORI THERAPEUTICS, INC. FORM 10Q FOR THE QUARTER ENDED SEPTEMBER 30, 2009 - PLUS THERAPEUTICS, INC. | form10_q093009.htm |
EXHIBIT
32.1
CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350/ SECURITIES EXCHANGE ACT RULE 13a-14(b),
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF
2002
In
connection with the Quarterly Report on Form 10-Q of Cytori Therapeutics, Inc.
for the quarterly period ended September 30, 2009 as filed with the Securities
and Exchange Commission on the date hereof, Christopher J. Calhoun, as Chief
Executive Officer of Cytori Therapeutics, Inc., and Mark E. Saad, as Chief
Financial Officer of Cytori Therapeutics, Inc., each hereby certifies,
respectively, that:
1.
|
The
Form 10-Q report of Cytori Therapeutics, Inc. that this certification
accompanies fully complies with the requirements of Section 13(a) of
the Securities Exchange Act of
1934.
|
2.
|
The
information contained in the Form 10-Q report of Cytori Therapeutics, Inc.
that this certification accompanies fairly presents, in all material
respects, the financial condition and results of operations of Cytori
Therapeutics, Inc.
|
By:
|
/s/
Christopher J. Calhoun
|
|
Dated:
November 9, 2009
|
Christopher
J. Calhoun
|
|
Chief
Executive Officer
|
||
By:
|
/s/
Mark E. Saad
|
|
Dated:
November 9, 2009
|
Mark
E. Saad
|
|
Chief
Financial Officer
|